Serina Therapeutics Inc（SER）財務資料SERSerina Therapeutics Inc

Evaluating the bottom line, Serina Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -305.13%, provide a clear picture of how effectively SER converts its operational activities into shareholder value.

In the context of the broader market, SER competes directly with industry leaders such as FJET and CIGL. With a market capitalization of $34.80M, it holds a significant position in the sector. When comparing efficiency, SER's gross margin of N/A stands against FJET's N/A and CIGL's -159.68%. Such benchmarking helps identify whether Serina Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a net income loss of $6.9 million in Q1 2026 and $8.9 million in Q2 2026, with total revenue of only $130,000 in Q2 2025, highlighting ongoing financial struggles.